New hope for tough leukemia: Triple-Drug combo trial opens
NCT ID NCT07133997
First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 23 times
Summary
This early-phase trial tests a combination of three drugs (asparaginase, venetoclax, and blinatumomab) in adults aged 12-55 whose B-cell acute lymphoblastic leukemia has returned or not responded to prior treatment. The goal is to find a safe dose and see if the combo can help the immune system kill cancer cells. About 26 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.